Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1994 Feb;62(2):449–456. doi: 10.1128/iai.62.2.449-456.1994

Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.

P Boucher 1, H Sato 1, Y Sato 1, C Locht 1
PMCID: PMC186128  PMID: 7507893

Abstract

The currently available diphtheria-tetanus-whole-cell pertussis (DTP) vaccines are associated with a variety of problems, including undesirable side effects and inconsistent efficacy. These problems are probably related to the poor definition of such vaccines, especially with respect to the whole-cell component against pertussis. Ideal vaccines should include only immunoprotective antigens with no toxin activity. As an initial step towards obtaining a well-defined and simplified DTP vaccine, a pertussis toxin-tetanus toxin chimeric protein was constructed. A soluble form of the pertussis toxin S1 subunit was fused to the protective fragment C of tetanus toxin, and the recombinant hybrid protein was produced in Escherichia coli. The 75-kDa fusion protein (p75) was overexpressed as a soluble molecule and purified to near homogeneity by two consecutive chromatographic steps. Purified p75 retained its ability to bind to ganglioside GT1b, the receptor for tetanus toxin, and to be recognized by protective and neutralizing anti-pertussis toxin antibodies specific for conformational epitopes. When administered to mice, the hybrid protein was found to be nontoxic but immunogenic. In addition, it was capable of inducing strong protection against tetanus and some protection against pertussis, as well as eliciting a pertussis toxin-neutralizing antibody response. Although the levels of anti-pertussis toxin antibodies were rather low, neutralizing titers of the immunized mice correlated well with anti-pertussis toxin titers, indicating that protective epitopes are conserved in the recombinant protein.

Full text

PDF
449

Images in this article

451Image
on p.451
452Image
on p.452

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antoine R., Locht C. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. Infect Immun. 1990 Jun;58(6):1518–1526. doi: 10.1128/iai.58.6.1518-1526.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Antoine R., Tallett A., van Heyningen S., Locht C. Evidence for a catalytic role of glutamic acid 129 in the NAD-glycohydrolase activity of the pertussis toxin S1 subunit. J Biol Chem. 1993 Nov 15;268(32):24149–24155. [PubMed] [Google Scholar]
  3. Arciniega J. L., Burns D. L., Garcia-Ortigoza E., Manclark C. R. Immune response to the B oligomer of pertussis toxin. Infect Immun. 1987 May;55(5):1132–1136. doi: 10.1128/iai.55.5.1132-1136.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Askelöf P., Rodmalm K., Wrangsell G., Larsson U., Svenson S. B., Cowell J. L., Undén A., Bartfai T. Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1. Proc Natl Acad Sci U S A. 1990 Feb;87(4):1347–1351. doi: 10.1073/pnas.87.4.1347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Audibert F., Jolivet M., Chedid L., Alouf J. E., Boquet P., Rivaille P., Siffert O. Active antitoxic immunization by a diphtheria toxin synthetic oligopeptide. Nature. 1981 Feb 12;289(5798):593–594. doi: 10.1038/289593a0. [DOI] [PubMed] [Google Scholar]
  6. Barbieri J. T., Armellini D., Molkentin J., Rappuoli R. Construction of a diphtheria toxin A fragment-C180 peptide fusion protein which elicits a neutralizing antibody response against diphtheria toxin and pertussis toxin. Infect Immun. 1992 Dec;60(12):5071–5077. doi: 10.1128/iai.60.12.5071-5077.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Barkin R. M., Pichichero M. E. Diphtheria-pertussis-tetanus vaccine: reactogenicity of commercial products. Pediatrics. 1979 Feb;63(2):256–260. [PubMed] [Google Scholar]
  8. Blackwelder W. C., Storsaeter J., Olin P., Hallander H. O. Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions. Am J Dis Child. 1991 Nov;145(11):1285–1289. doi: 10.1001/archpedi.1991.02160110077024. [DOI] [PubMed] [Google Scholar]
  9. Blennow M., Hedenskog S., Granström M. Protective effect of acellular pertussis vaccines. Eur J Clin Microbiol Infect Dis. 1988 Jun;7(3):381–383. doi: 10.1007/BF01962341. [DOI] [PubMed] [Google Scholar]
  10. Burnette W. N., Cieplak W., Mar V. L., Kaljot K. T., Sato H., Keith J. M. Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope. Science. 1988 Oct 7;242(4875):72–74. doi: 10.1126/science.2459776. [DOI] [PubMed] [Google Scholar]
  11. Cody C. L., Baraff L. J., Cherry J. D., Marcy S. M., Manclark C. R. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics. 1981 Nov;68(5):650–660. [PubMed] [Google Scholar]
  12. De Magistris M. T., Romano M., Bartoloni A., Rappuoli R., Tagliabue A. Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map. J Exp Med. 1989 May 1;169(5):1519–1532. doi: 10.1084/jem.169.5.1519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fairweather N. F., Lyness V. A., Maskell D. J. Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect Immun. 1987 Nov;55(11):2541–2545. doi: 10.1128/iai.55.11.2541-2545.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fulginiti V. A. Pertussis disease, vaccine, and controversy. JAMA. 1984 Jan 13;251(2):251–251. [PubMed] [Google Scholar]
  15. Halpern J. L., Habig W. H., Neale E. A., Stibitz S. Cloning and expression of functional fragment C of tetanus toxin. Infect Immun. 1990 Apr;58(4):1004–1009. doi: 10.1128/iai.58.4.1004-1009.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Halpern J. L., Loftus A. Characterization of the receptor-binding domain of tetanus toxin. J Biol Chem. 1993 May 25;268(15):11188–11192. [PubMed] [Google Scholar]
  17. Helting T. B., Zwisler O. Structure of tetanus toxin. I. Breakdown of the toxin molecule and discrimination between polypeptide fragments. J Biol Chem. 1977 Jan 10;252(1):187–193. [PubMed] [Google Scholar]
  18. Hewlett E. L., Sauer K. T., Myers G. A., Cowell J. L., Guerrant R. L. Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin. Infect Immun. 1983 Jun;40(3):1198–1203. doi: 10.1128/iai.40.3.1198-1203.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kimura A., Mountzouros K. T., Schad P. A., Cieplak W., Cowell J. L. Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen. Infect Immun. 1990 Oct;58(10):3337–3347. doi: 10.1128/iai.58.10.3337-3347.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kimura M. Japanese clinical experiences with acellular pertussis vaccines. Dev Biol Stand. 1991;73:5–9. [PubMed] [Google Scholar]
  21. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  22. Lang A. B., Ganss M. T., Cryz S. J., Jr Monoclonal antibodies that define neutralizing epitopes of pertussis toxin: conformational dependence and epitope mapping. Infect Immun. 1989 Sep;57(9):2660–2665. doi: 10.1128/iai.57.9.2660-2665.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Locht C., Capiau C., Feron C. Identification of amino acid residues essential for the enzymatic activities of pertussis toxin. Proc Natl Acad Sci U S A. 1989 May;86(9):3075–3079. doi: 10.1073/pnas.86.9.3075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Locht C., Cieplak W., Marchitto K. S., Sato H., Keith J. M. Activities of complete and truncated forms of pertussis toxin subunits S1 and S2 synthesized by Escherichia coli. Infect Immun. 1987 Nov;55(11):2546–2553. doi: 10.1128/iai.55.11.2546-2553.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Locht C., Lobet Y., Feron C., Cieplak W., Keith J. M. The role of cysteine 41 in the enzymatic activities of the pertussis toxin S1 subunit as investigated by site-directed mutagenesis. J Biol Chem. 1990 Mar 15;265(8):4552–4559. [PubMed] [Google Scholar]
  26. Loosmore S. M., Zealey G. R., Boux H. A., Cockle S. A., Radika K., Fahim R. E., Zobrist G. J., Yacoob R. K., Chong P. C., Yao F. L. Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccine. Infect Immun. 1990 Nov;58(11):3653–3662. doi: 10.1128/iai.58.11.3653-3662.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Miller D. L., Ross E. M., Alderslade R., Bellman M. H., Rawson N. S. Pertussis immunisation and serious acute neurological illness in children. Br Med J (Clin Res Ed) 1981 May 16;282(6276):1595–1599. doi: 10.1136/bmj.282.6276.1595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Nicosia A., Bartoloni A., Perugini M., Rappuoli R. Expression and immunological properties of the five subunits of pertussis toxin. Infect Immun. 1987 Apr;55(4):963–967. doi: 10.1128/iai.55.4.963-967.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Olander R. M., Muotiala A., Himanen J. P., Karvonen M., Airaksinen U., Runeberg-Nyman K. Immunogenicity and protective efficacy of pertussis toxin subunit S1 produced by Bacillus subtilis. Microb Pathog. 1991 Feb;10(2):159–164. doi: 10.1016/0882-4010(91)90076-m. [DOI] [PubMed] [Google Scholar]
  30. Pizza M., Bartoloni A., Prugnola A., Silvestri S., Rappuoli R. Subunit S1 of pertussis toxin: mapping of the regions essential for ADP-ribosyltransferase activity. Proc Natl Acad Sci U S A. 1988 Oct;85(20):7521–7525. doi: 10.1073/pnas.85.20.7521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Pizza M., Covacci A., Bartoloni A., Perugini M., Nencioni L., De Magistris M. T., Villa L., Nucci D., Manetti R., Bugnoli M. Mutants of pertussis toxin suitable for vaccine development. Science. 1989 Oct 27;246(4929):497–500. doi: 10.1126/science.2683073. [DOI] [PubMed] [Google Scholar]
  32. Quentin-Millet M. J., Arminjon F., Danve B., Cadoz M., Armand J. Acellular pertussis vaccines: evaluation of reversion in a nude mouse model. J Biol Stand. 1988 Apr;16(2):99–108. doi: 10.1016/0092-1157(88)90037-6. [DOI] [PubMed] [Google Scholar]
  33. Sato H., Ito A., Chiba J., Sato Y. Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections. Infect Immun. 1984 Nov;46(2):422–428. doi: 10.1128/iai.46.2.422-428.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sato H., Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect Immun. 1984 Nov;46(2):415–421. doi: 10.1128/iai.46.2.415-421.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sato H., Sato Y., Ito A., Ohishi I. Effect of monoclonal antibody to pertussis toxin on toxin activity. Infect Immun. 1987 Apr;55(4):909–915. doi: 10.1128/iai.55.4.909-915.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Sato H., Sato Y., Ohishi I. Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies. Infect Immun. 1991 Oct;59(10):3832–3835. doi: 10.1128/iai.59.10.3832-3835.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sato H., Sato Y. Protective activities in mice of monoclonal antibodies against pertussis toxin. Infect Immun. 1990 Oct;58(10):3369–3374. doi: 10.1128/iai.58.10.3369-3374.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Sato Y., Kimura M., Fukumi H. Development of a pertussis component vaccine in Japan. Lancet. 1984 Jan 21;1(8369):122–126. doi: 10.1016/s0140-6736(84)90061-8. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES